YBX1 and melanoma: Knockdown of NONO/RALY complex components reversed YB-1 overexpression-induced oxaliplatin resistance in CRC cells [37], while NONO silencing modulated the cellular response to ultraviolet-induced DNA damage in melanoma cells [38].